Alkermes to Present at Jefferies 2011 Global Healthcare Conference

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Wednesday, Sept. 28, 2011, at 12:20 p.m. BST (7:20 a.m. ET) from London. The webcast may be accessed from the investor relations section on www.alkermes.com and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.



CONTACT:

Alkermes plc
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS:   United Kingdom  United States  Europe  North America  Massachusetts  Ireland

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.